The first stage of testing the Sputnik V vaccine in the 12-17 age group has been successfully completed in Russia.
The press service of the Mayor of Moscow reports encouraging results: the drug forms excellent post-vaccination cellular immunity, says RIA News… The study involved 99 children aged 12-17 years, 43 girls and 56 boys, 92 children received both doses. The vaccine volume was 1/10 or 1/5 of the adult dose. The message says:
“The results of the first stage of the study allow us to conclude that two-fold vaccination of volunteers with vaccines of both 1/10 and 1/5 of the immunizing dose, aimed at adults, can lead to the formation of good post-vaccination cellular immunity. The drug has shown a favorable safety and immunogenicity profile. Safety indicators and immunogenicity is superior to that in adult participants in a similar Phase 1-2 study. “
The second stage of Sputnik V testing will begin shortly, and a preliminary selection of volunteers is underway.